skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery

Journal Article · · New Engl. J. Med.; (United States)

Within three weeks of definitive surgical intervention, 467 patients with histologically proved malignant glioma were randomized to receive one of four treatment regimens: semustine (MeCCNU), radiotherapy, carmustine (BCNU) plus radiotherapy, or semustine plus radiotherapy. We analyzed the data for the total randomized population and for the 358 patients in whom the initial protocol specifications were met (the valid study group). Observed toxicity included acceptable skin reactions secondary to radiotherapy and reversible leukopenia and thrombocytopenia due to chemotherapy. Radiotherapy used alone or in combination with a nitrosourea significantly improved survival in comparison with semustine alone. The group receiving carmustine plus radiotherapy had the best survival, but the difference in survival between the groups receiving carmustine plus radiotherapy and semustine plus radiotherapy was not statistically significant. The combination of carmustine plus radiotherapy produced a modest benefit in long-term (18-month) survival as compared with radiotherapy alone, although the difference between survival curves was not significant at the 0.05 level. This study suggests that it is best to use radiotherapy in the post-surgical treatment of malignant glioma and to continue the search for an effective chemotherapeutic regimen to use in addition to radiotherapy.

Research Organization:
National Cancer Inst., Bethesda, MD
OSTI ID:
6920541
Journal Information:
New Engl. J. Med.; (United States), Vol. 303:23
Country of Publication:
United States
Language:
English

Similar Records

The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma
Journal Article · Thu Sep 01 00:00:00 EDT 2005 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:6920541

Hyperfractionated radiaton therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma - possible advantage observed at 72. 0 Gy in 1. 2 Gy B. I. D. fractions: Report of the radiation therapy oncology group protocol 8302
Journal Article · Fri Jan 15 00:00:00 EST 1993 · International Journal of Radiation Oncology, Biology and Physics; (United States) · OSTI ID:6920541

Radiation plus adjuvant CCNU (1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea) vs CCNU, hydroxyurea and vincristine in the treatment of malignant glioma
Conference · Sat Sep 01 00:00:00 EDT 1979 · Int. J. Radiat. Oncol., Biol. Phys.; (United States) · OSTI ID:6920541